The global desalting and buffer exchange market was estimated at USD 1.11 billion in 2023 and is projected to reach USD 2.18 billion by 2030, expanding at a CAGR of 10.2% from 2024 to 2030. Market growth is primarily driven by the rising demand for efficient bioprocessing techniques across the pharmaceutical and biotechnology industries, where high-purity biological samples are essential for downstream processing.

Desalting and buffer exchange processes play a critical role in biological sample preparation by enabling the removal of impurities and facilitating buffer replacement during downstream bioprocessing. The increasing production of monoclonal antibodies and the continuous development of novel biopharmaceutical products have significantly accelerated the adoption of advanced desalting and buffer exchange technologies.

Key Market Trends & Insights

• Asia Pacific dominated the global market with a 37.7% revenue share in 2023, supported by expanding biopharmaceutical manufacturing and research activities.
• By product, the cassettes & cartridges segment led the market, accounting for 24.1% of global revenue in 2023.
• By technique, the filtration segment held the largest share, contributing 43.7% of global revenue in 2023.
• By application, bioprocessing emerged as the leading segment with a 37.5% revenue share in 2023.

Market Size & CAGR

• 2023 Market Size: USD 1.11 Billion
• 2030 Projected Market Size: USD 2.18 Billion
• CAGR (2024–2030): 10.2%
• Largest Regional Market (2023): Asia Pacific

The continued expansion of the global bioprocessing sector, particularly in emerging economies, is expected to further boost demand for desalting and buffer exchange products and technologies. Advancements in biotechnology research, coupled with the growing emphasis on personalized medicine, are also contributing to sustained market growth. Rapid technological developments in genomics, biotechnology, and artificial intelligence have made genome sequencing and large-scale health data analysis more accessible and cost-effective, enabling highly targeted therapeutic approaches.

As personalized medicine requires greater sample specificity and purity, the demand for advanced desalting and buffer exchange techniques continues to rise. Additionally, stringent regulatory requirements related to process validation and quality control have increased the need for reliable and efficient desalting and buffer exchange solutions to ensure compliance and preserve product integrity.

Order a free sample PDF of the Desalting And Buffer Exchange Market Intelligence Study, published by Grand View Research.

Key Desalting and Buffer Exchange Company Insights

Several established and emerging players are actively shaping the competitive landscape of the market, including GE Healthcare, Thermo Fisher Scientific, and Danaher, among others.

• GE Healthcare offers a broad portfolio of desalting and buffer exchange solutions tailored for bioprocessing applications. Its strong focus on innovation and customer-centric solutions has reinforced its market position.
• Thermo Fisher Scientific is a global leader in biotechnology solutions, providing an extensive range of desalting and buffer exchange products across pharmaceutical, biotechnology, academic, government, and industrial sectors.
• Sartorius AG specializes in membrane filtration systems, with a strong emphasis on single-use technologies and scalable solutions that support its market growth.
• Biotage focuses on purification technologies within the chemistry, pharmaceutical, and biotechnology domains, offering innovative desalting and buffer exchange solutions that support research and therapeutic development.
• Other notable participants include Avantor Inc., PhyNexus Inc., Bio-Rad Laboratories, Agilent Technologies Inc., Norgen Biotek Corp., Bio-Works Technologies AB, and Repligen Corporation.

Key Desalting and Buffer Exchange Companies

• Thermo Fisher Scientific
• Merck
• GE Healthcare
• Danaher
• Sartorius
• Avantor Inc.
• Bio-Rad Laboratories
• Agilent Technologies Inc.
• PhyNexus Inc.
• Biotage
• Norgen Biotek Corp.
• Bio-Works Technologies AB
• Repligen Corporation

Conclusion

In conclusion, the desalting and buffer exchange market is positioned for robust growth through 2030, driven by rising bioprocessing demand, expanding biopharmaceutical production, and the increasing adoption of personalized medicine. Technological advancements, regulatory compliance requirements, and strong growth in Asia Pacific are further strengthening market momentum. As bioprocessing workflows become more complex and precision-driven, advanced desalting and buffer exchange solutions will remain critical to ensuring product quality, process efficiency, and regulatory adherence across the global life sciences industry.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.